Business
Telix (ASX:TLX) share price slips despite priority review status
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading.
This comes despite the company reporting it had received priority review status from Australia’s Therapeutic Goods Administration (TGA) for its prostate cancer imaging product, TLX591-CDx.
The priority review provides Telix with a fast-tracked timeframe of 150 working days for its product dossier review and approval.
It’s possible this news was already factored into the share price. Telix shares soared 121% higher in the month of November, and the share price is up 152% year-to-date. By comparison, the S&P/ASX 200 Index (ASX: XJO) is flat since 2 January.
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals is a…
-
General22 hours agoPolice offer ‘surrender plan’ to Dezi Freeman as fugitive avoids capture for another day
-
General20 hours agoGeelong Cats AFL star Bailey Smith details mental health battle during All-Australian speech
-
Noosa News12 hours agoBrisbane nation’s third-youngest capital; Leaders condemn anti-immigration rally
-
Noosa News20 hours agoQld nurses poised to strike deal with Crisafulli government